What is the Lille score and how is it used to assess response to corticosteroid therapy in severe alcoholic hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is a Lille Score?

The Lille score is a prognostic model calculated on day 7 of corticosteroid treatment in severe alcoholic hepatitis that predicts 6-month mortality and identifies patients who are not responding to therapy, with a score ≥0.45 indicating treatment failure and warranting cessation of corticosteroids. 1

Purpose and Clinical Use

The Lille score serves as an on-treatment prognostic tool specifically designed to assess therapeutic response to corticosteroids in patients with severe alcoholic hepatitis (Maddrey score ≥32). Unlike pre-treatment scores (mDF, MELD, GAHS, ABIC) that predict baseline mortality risk, the Lille score incorporates early changes in liver function during the first week of treatment to identify non-responders 2.

Calculation Formula

The Lille score uses the following variables 2:

R = 3.19 – 0.101 × age (years) + 0.147 × albumin day 0 (g/L) + 0.0165 × (bilirubin day 0 – bilirubin day 7 in μmol/L) – 0.206 × renal insufficiency – 0.0065 × bilirubin day 0 (μmol/L) – 0.0096 × PT (seconds)

Lille score = exp(–R) / [1 + exp(–R)]

  • Renal insufficiency is coded as 0 if creatinine <1.3 mg/dL or 1 if ≥1.3 mg/dL
  • Evolution in bilirubin = bilirubin level on day 0 minus day 7

Interpretation and Mortality Risk

Critical thresholds 1:

  • Lille score <0.45 (Responders): 6-month survival of 70-80%
  • Lille score ≥0.45 (Non-responders): 6-month survival of only 20-30%
  • Lille score ≥0.56 (Null responders): Corticosteroids are no more effective than placebo; must stop steroids immediately 1
  • Lille score 0.45-0.56: Consider stopping corticosteroids on a case-by-case basis 1

The original validation study showed the Lille model identifies approximately 75% of observed deaths with typically 75% mortality within 6 months if score ≥0.45 2, 3.

Timing of Assessment

Standard practice: Calculate on day 7 of corticosteroid therapy 1

Emerging evidence: Recent studies suggest the Lille score can be calculated as early as day 4 with similar prognostic accuracy 1, 4, 5, 6. One study showed day 4 Lille had comparable area under ROC curve (0.77 vs 0.75, P=0.558) with 90.3% concordance with day 7 assessment 5, 6. However, the 2022 French guidelines note this requires further validation before routine implementation 1.

Even earlier assessment at day 2 shows promise, with one 2025 study demonstrating 85% concordance with day 7 and similar predictive accuracy (AUC 0.818 vs 0.809) 7.

Clinical Decision-Making Algorithm

When Lille score ≥0.56:

  • Stop corticosteroids immediately - these patients derive no benefit and face unnecessary infection risk 1

When Lille score 0.45-0.56:

  • Individualized decision required
  • Consider stopping if clinical deterioration or infection develops
  • Weigh infection risk against potential marginal benefit

When Lille score <0.45:

  • Continue prednisolone 40mg daily (or methylprednisolone 32mg daily) for full 28-day course 1
  • These patients benefit from corticosteroid therapy

Combining with Other Scores

The 2022 French guidelines strongly recommend combining Lille and MELD scores for optimal mortality prediction 1. This joint-effect model outperforms either score alone and is particularly valuable for selecting candidates for early liver transplantation 1, 4. For example, a patient with MELD 21 and Lille 0.45 has 1.9-fold higher 2-month mortality risk than one with MELD 21 and Lille 0.16 (23.7% vs 12.5%) 4.

Common Pitfalls

Infection screening is mandatory before calculating the Lille score 1. Perform comprehensive bacteriological workup (blood cultures, urine culture, ascites fluid analysis) as 20-30% of patients have infection at admission and 25% develop infection during the first month of corticosteroid treatment 1. Infection developed under corticosteroids significantly increases short-term mortality risk 1.

Do not use the Lille score for initial treatment decisions - it is an on-treatment assessment tool, not a pre-treatment prognostic score 2. Use mDF ≥32 or MELD >20 to determine initial corticosteroid eligibility 4.

The Lille score has excellent sensitivity (95%) but poor specificity (19%) for predicting 30-day survival, meaning it reliably identifies responders but less accurately identifies non-responders 8. This supports its primary use as a stopping rule rather than a continuation rule.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.